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As early as in 1836, Sir Richard Bright highlighted the intricate link between heart and kidney function, making astute observations about a myriad of structural changes in the
hearts in patients with shrunken kidneys [1]. Since that notation in the literature, the field of cardiorenal medicine has
seen major developments in defining mechanisms of heartkidney cross talk, based on a strong foundation of physiological experiments in the early 1900s, that have set the stage
for our current understanding of the pathophysiology of cardiorenal syndrome via hemodynamic, inflammatory and maladaptive neurohormonal pathways [2]. These observations
were further studied and validated in clinical settings and
have formed the basis for phenotyping cardiorenal syndrome
(CRS) into subtypes based on the “primum movens” of the
disease (heart vs kidney), acuity of the syndrome and the presence or absence of systemic multi-organ involvement [3]. In
parallel, the field of cardio-renal disease has extended beyond
the syndrome itself which centrally revolves around the kidneys’ response to the failing heart, to the study of all phenotypes of cardiovascular disease in patients with kidney disease
including coronary artery disease, valvopathies and arrythmias, healthcare resource utilization, economics and precision medicine profiling of patients with dual heart and kidney disease. This expanded scope has been inevitable, given
the increasing prevalence of vascular risk factors such as diabetes, hypertension and obesity which form the common soil
for the development and maintenance of cardiovascular and
kidney disease. The rapidly expanding scope of cardiorenal
medicine now involves early risk mitigation (primordial as
well as primary prevention), aggressive secondary prevention, cardiorenal therapeutics in the high-risk patient such
as dialytic therapies in patients with left ventricular assist devices and emphasis on patient and caregiver involvement in
decision- making, as part of a multidisciplinary care approach
with emphasis on personalized goals and quality of life. SuRev. Cardiovasc. Med. 2021 vol. 22(2), 257-258
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perimposed on the existing landscape of cardio-renal disease,
the added burden imposed by COVID-19 has brought the
current limitations of health care delivery, sub-optimal cardiorenal risk factor control and care fragmentation in patients
with complex cardiorenal disease to the forefront, highlighting the urgent need for an overhaul towards our approach to
optimizing care in these vulnerable patients [4].
In this context, this special issue of Reviews in Cardiovascular Medicine brings together several leading thought leaders in
cardiology and nephrology, who have converged their expertise across several key topics of interest, making this collection of articles timely, relevant and practice changing. Several
takeaway messages from this collection are worth an in-depth
read to solidify the understanding of the importance of a multidisciplinary approach to key controversies and concepts in
the cardiorenal space.
Heart-kidney hemodynamics and the nuances of disease
modifying therapies in CRS occupy forefront attention with
the manuscripts by Kazory A and Costanzo MR describing
the role of chloride as a cardiorenal connector, prognostic
marker and potential therapeutic target [5]. Toroghi HM. et
al. [6] describe the use of newer predictors of kidney function
in patients with heart failure with preserved ejection fraction
such as pulmonary artery capacitance. This sheds light on
the utility of newer markers of right ventricular function as
potential options for kidney function prognostication across
the spectrum of heart failure irrespective of ejection fraction
and may have implications on selection of guideline directed
medical therapies (GDMT) for these patients. The maintenance, up-titration and de-escalation of renin angiotensin
system inhibitors is a subject of clinical uncertainty in real
world practice with differing practice patterns between cardiology and nephrology. To that end, the review by Singhania G et al. on the continuation of renin angiotensin system
inhibitors (RASi) in patients with acute heart failure (AHF)
is an important contribution to the literature and emphasizes
the need to ensure that vulnerable patients with AHF benefit
from the continuation of GDMT, as well as appropriate decongestive therapies. Along the same vein, the manuscript by
Lo KB et al. [7] describes RASi usage patterns in AHF with

data from right heart catheterizations delineating hemodynamic profiles in these patients and confirming the deleterious effects of persistent congestion and withdrawal of RASi
in the setting of AHF, which include high rates of inpatient
mortality as well as 6-month HF re-admissions. The management of HF in patients with ESKD assumes a higher level of
complexity with challenges towards ascertaining an accurate
diagnosis, implementing GDMT with limited high-quality
data given exclusion of these patients from major RCTS in
HF, and focusing on patient goals and quality of life. In their
detailed review on this topic, Joseph MS et al. [8] bring out
the nuances on the diagnosis and management of heart failure (HF) in ESKD using a practical and data driven approach,
which will undoubtedly be an extremely valuable resource to
cardiologists and nephrologists caring for these high-risk patients.
The importance of CKD as an independent risk factor for
coronary artery disease (CAD) has been well delineated in
the literature. However not much attention is paid to the
high burden of coronary microvascular dysfunction in patients with CKD. In their manuscript on accelerated and intensified calcific atherosclerosis and microvascular dysfunction in patients with CKD, Fakhry M. et al. [9] elegantly
describe the pathophysiological processes that drive the accelerated and disproportionate burden of CAD in CKD with
emphasis on future areas for study in microvascular dysfunction. Finally, the importance of insulin resistance as a key
element contributing to the elevated cardiovascular disease
risk in CKD and glomerular hyperfiltration and the utility of
high sensitivity troponin assays in CKD by Adeva-Andany
M. et al. and Chuang A. et al. [10] respectively are reflective
of the emerging role of biomarkers of cardiorenal disease that
will help shape our understanding of the complex cross talk
between the heart and kidneys in the future.
In summary, this special issue of the Reviews in Cardiovascular Medicine provides a panoramic view of current concepts and future directions in cardiorenal medicine, across
several interfaces of heart-kidney disease. The contributing
authors are to be congratulated for their valuable contributions to this effort, which will help integrate these practice
changing data into clinical care, resulting in optimal and coordinated multidisciplinary care for vulnerable patients with
cardio-renal disease.
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